Cobalis gets positive Phase III results on PreHistin

Anti-allergy specialist Cobalis announced that data from its Phase III clinical trial show that preseasonal treatment with PreHistin, its flagship anti-allergy medication, clearly reduced allergy symptoms. The study showed that patients using PreHistin had "significant" reduction in perceived symptoms. The results include only patient-reported data; the company expects to announce analysis of data from clinical exams and blood samples within six weeks.

- read this press release for more

Suggested Articles

Sarepta will negotiate a warning for golodirsen rather than carry out more studies. But the implications of the rejection range beyond golodirsen.

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.